Mr. Ero is the CEO of Machaon Diagnostics, a company he founded in 2003. He has built a solutions-based, team approach to laboratory medicine, designing new and innovative laboratory strategies to meet unmet needs in the healthcare and bioscience industries. He is a laboratory expert with over 25 years of healthcare experience. Mr. Ero leads a team with over 400 aggregate years of experience in specialized laboratory diagnostics and genetics. Under his leadership, Machaon Diagnostics’ scientists and physicians have pioneered multiple disruptive laboratory techniques and processes that have revolutionized how life-threatening diseases can be managed and characterized. Machaon Diagnostics has been the contract laboratory or primary contract research organization (CRO) on over 250 clinical trials and studies with physical, molecular, immunologic, platelet and special coagulation endpoints. Clients include Fortune 500 pharmaceutical and biotechnology firms and large academic medical centers, hospital systems, multinational CROs and national/international reference laboratories. Mr. Ero speaks regularly at national and international scientific conferences and has over 30 scientific publications.
Prior to founding Machaon Diagnostics, Mr. Ero was vice president of the Coagulation Center, Inc. of Oakland, California prior to its acquisition by Quest Diagnostics (NYSE:DGX). He has held past clinical and research roles with The Scripps Research Institute, Loyola University Medical Center and the University of Illinois, Chicago. Mr. Ero is the founder and board chairman of Labs4Free, a charitable organization (501c3) that provides laboratory services to underserved populations.
He holds an MBA from Babson College, a certificate in Healthcare Strategy from Harvard Business School and a BS in medical technology from Michigan State University. He is a licensed clinical laboratory scientist (CLS) and a board-certified (ASCP) medical technologist. Mr. Ero has been an inspector for the College of American Pathologists (CAP) for over 20 years. He is also a good laboratory practices (GLP) auditor and an FDA and EMA regulatory affairs consultant.
He loves spending time with his wife and son. Mike is an avid golfer, skier, youth baseball and soccer coach and has completed over 12 triathlons as an amateur triathlete.
Dr. Lewis is the Medical Director of Machaon Diagnostics. Dr. Lewis is an expert in benign hematology with a focus on thrombosis and hemostasis. He regularly lectures around the US and internationally on the clinical and laboratory approaches to diagnosing atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). He is Professor Emeritus in Medicine/Hematology at University of California at San Francisco. He was the Regional Benign Hematology Expert for Kaiser Permanente Medical Group of Northern California. Dr. Lewis has provided clinical consultation on the majority of the thousands of suspected cases of aHUS sent to Machaon Diagnostics for complement and coagulation gene sequencing. He has developed a unique-to-Machaon expertise in the use of genetic sequencing data in the acute clinical setting when diagnosis has yet to be established. See our aHUS Genetic Panel (48-hour STAT) for more information.
Dr. Lewis holds a BS in History and biochemistry from MIT, an MA from Brandeis University and an MD from the UCLA School of Medicine. He completed his residency and Hematology fellowship at the University of Rochester.
Brad can be reached at firstname.lastname@example.org
Adam Hand is National Sales Director for Machaon Diagnostics. Adam is responsible for leading the sales operations for Machaon Diagnostics, including training, identifying key markets, monitoring emerging trends, and cross functional collaboration.
Adam comes to Machaon with 15+ years experience in the healthcare industry. Adam joined Machaon Diagnostics in October 2021. Prior to Machaon, Adam was Regional Sales Director with LabCorp. Adam’s past experience also include BD Medical, ARUP Laboratories, and Beckman Coulter. Adam enjoys spending time with his wife and 2 children. Adam is an avid golfer and outdoorsman.
Adam received his B.S. in Marketing from Mississippi State University and his MBA from Belhaven University.
Yamini Bynagari, PhD
Dr. Yamini Bynagari is Vice President of Clinical Research at Machaon Diagnostics. Dr. Bynagari is a internationally recognized expert in the field of thrombosis and hemostasis. She manages the contract research organization (CRO) assay development experimental design effort at Machaon Diagnostics. Her expertise includes thrombin generation, platelet activation signal transduction and coagulation protein biochemistry. Dr. Bynagari was a joint postdoctoral scholar at Pfizer Center for Therapeutic Innovation and UCSF where she worked with Dr. Shaun Coughlin in the Cardiovascular Research Institute. Dr. Bynagari has published her research in Blood, the Journal of Biological Chemistry and the Journal for Thrombosis and Haemostasis in addition to other high-impact scientific journals. She is a peer-reviewer of Thrombosis Research, Journal of Receptors and Signal Transduction.
Dr. Bynagari holds a PhD in Molecular and Cellular Physiology from Temple University and a BS in Industrial Biotechnology from Anna University in Chennai, India.
Jamey Kain, PhD
Dr. Jamey Kain is Vice President of Genetic Innovation at Machaon Diagnostics. He leads the effort to clinically validate various rapid genetic sequencing services associated with thrombotic disorders. Dr. Kain’s publications include articles in Nature, PNAS and several other scientific journals.
Dr. Kain comes from a diverse academic background. He completed a postdoctoral fellowship where he used machine vision, machine learning and automation to study the roles of nature, nurture and noise in behavior at Harvard University. Dr. Kain holds a PhD in Biochemistry and a MA in Biology from Harvard where he studied the role of proteolysis during bacterial development. As an undergraduate (BA in Molecular and Cellular Biology from the University of California, Berkeley), he had the good fortune to study aging and DNA damage under Prof. Bruce Ames, the inventor of the famous Ames test.
Violet Votin, PhD
Dr. Votin joined Machaon Diagnostics as Clinical Research Scientist in 2016 to be involved in new clinically useful diagnostic tests, which are the foundation of the exciting revolution known as precision medicine. Violet has specialized in next generation sequencing for certain rare diseases and other cutting-edge technologies. She currently develops and validates genetic tests as well as interpreting and analyzing genetic results, contributing data to several clinical trials and to the current knowledge in the field.
Dr. Votin earned her PhD in cellular and molecular physiology from Stanford University School of Medicine, where she was awarded a predoctoral fellowship from the National Institutes of Health. During her postdoctoral fellowship at the University of California in Berkeley, she rounded out her expertise in cell biology and microscopy with the approaches of genetics and biochemistry. She then applied her knowledge in industry and government labs to developing dozens of new research tools (including flow cytometry assays for human immune cells), new antibodies to diagnose botulism in the field and new platforms to discover novel therapeutic antibodies.
Violet enjoys the Bay Area for the scenic hiking opportunities, in addition to the vibrant biotech research culture.
Gloria Coker, MD
Dr. Coker is the Medical Director of Louisiana Coagulation, a division of Machaon Diagnostics. Dr. Coker took on this role in 2016 after having founded and lead Louisiana Coagulation since its founding in 1991. Dr. Coker is internationally recognized for her expertise in thrombosis and hemostasis. Dr. Coker is a pathologist and also a Clinical Assistant Professor of Medicine in Hematology/Medical Oncology at Tulane University Health Sciences Center. Dr. Coker holds a medical license from the Louisiana State Board of Medical Examiners and certifications from the American Board of Clinical & Anatomical Pathology and The International Board of Clinical & Applied Thrombosis Hemostasis and Vascular Medicine.
Dr. Coker received her medical degree from Tulane Medical School and completed her internship and residency in Pathology at Ochsner Foundation Hospital in New Orleans.
Delanda Burgess is the Director of Human Resource of Machaon Diagnostics. Delanda is responsible for onboarding support, performance guidance, as well as supporting corporate and departmental policies and procedures. Delanda is also responsible for ensuring that the overall administration, coordination, and evaluation of human resource plans and programs are realized.
Delanda Burgess holds a Bachelor of Science in Business Management from Saint Mary’s College, and a Master of Science in Human Services with a specialization in Social and Community Services from Capella University. Delanda also completed an HR Leadership Management Certificate program through Cornell University and obtained six human resource certificates.
Delanda enjoys spending time with her family and friends, traveling, reading books with a book club, and assisting the community.
Connie Ng, CLS
Connie Ng is a clinical laboratory scientist (CLS) at Machaon Diagnostics and Director of Clinical Lab Operations. She is a specialist in special coagulation and next generation sequencing. She has been trained in Good Clinical Laboratory Practices (GCLP) such as GLP, GCP, GDocP and other regulatory requirements for clinical trial operations and data management.
Ms. Ng holds a BS in Molecular and Cell Biology from the University of California, Berkeley and is a California-licensed clinical laboratory scientist. She is enrolled in the MPH program at University of California, Berkeley.
Bjorn Stromsness is the Senior Director of Client Services at Machaon Diagnostics. In this capacity he is involved in contracting, client services and corporate relationship management. He is also involved in identifying new service opportunities and communicating how rapid turnaround times can lead to better patient outcomes and new found efficiencies for healthcare providers of all shapes and sizes.
Mr. Stromsness received a BA in History and International Studies from Sonoma State University. Before joining Machaon Diagnostics, Mr. Stromsness was the Director of Business Development at a Silicon Valley enterprise software startup. He also has extensive nonprofit experience, having worked in development and program capacities for Friends of the River, Community Foundation Silicon Valley and the Shasta Regional Community Foundation.
Mr. Stromsness enjoys fly fishing, writing and cooking.
Bjorn can be reached at email@example.com
Timothy Shurtleff, MPA
Timothy Shurtleff is Machaon Diagnostics’ Vice President of Administration, managing our billing & financial activities, health policy & government affairs analysis and administrative functions.
Mr. Shurtleff holds BAs in Business Economics and Psychology from University of California, Santa Barbara and a Masters in Public Administration from California State University, East Bay. His previous employment includes the City of Livermore Housing & Human Services Division and the Oakland-based nonprofit First Place for Youth. Mr. Shurtleff is a founding member of Labs4Free, a charitable organization that provides laboratory services to underserved populations.
Mr. Shurtleff enjoys the great outdoors, traveling, and sports, especially of the fantasy variety.
Jooeun Lim Conley, PhD
Dr. Jooeun Lim Conley is Director of Bioinformatics at Machaon Diagnostics. Dr. Conley is deeply involved with our Next Generation Sequencing work, running both clinical and research samples. Dr. Conley has been published in the Journal of Biological Chemistry and Molecular Microbiology. Prior to pursuing her PhD, Dr. Conley worked at the Paul Prince Laboratory at the University of California, San Diego.
Dr. Conley holds a PhD in Biochemistry from Harvard University, an MA in Biology from Harvard University, and a BA in Biochemistry and Cell Biology from the University of California, San Diego.
Walter Jeske, PhD
Dr. Jeske assists Machaon Diagnostics with the planning and execution of clinical trials and contract research studies. He is an associate professor in the Department of Thoracic and Cardiovascular Surgery and Pathology at Loyola University Medical Center. He has been principal or co-investigator on over 40 clinical trials and studies. Dr. Jeske has authored or co-authored over 400 articles, book chapters and abstracts in the fields of thrombosis, hemostasis and platelet pathophysiology.
Dr. Jeske holds a PhD in Pharmacology from Loyola University, Chicago and a BS in Biochemistry from Illinois Benedictine College.
Specimen processing is one of the most important aspects in the generation of accurate and reliable lab results. Many variables, such as, anticoagulant ratio, storage time and temperature, and surface of containers and drawing components can affect test results.
Machaon Diagnostics follows and recommends the use of the third edition of the National Committee for Clinical Laboratory Standards (NCCLS) guideline H21-A3: Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays.
Frozen Citrated Plasma
Frozen citrated plasma is the specimen of choice for clotting assays and some ELISA testing. The anticoagulant used for these assays is 105 – 109 mmol/L, 3.13% – 3.2% of the dihydrate form of trisodium citrate (Na3C6H5O7 2H2O), buffered or nonbuffered.
Patients with hematocrit values above 55% should have their final citrate concentration corrected using the following equation:
X = (100 – PCV) / (595 – PCV) WB Volume
Where X is citrate volume required to prepare a whole blood volume (WB Volume) from a patient with a certain percent packed cell volume (PCV).
Please follow the listed suggestions for collection of citrated plasma samples.
A 1:9 ratio of anticoagulant to whole blood is imperative
Blood should be drawn directly into anticoagulant if possible
Syringe draws should be added to anticoagulant within 1 minute
Syringe draws should use no more that a 20mL volume syringe
A two-syringe technique is preferred for syringe draws
Coagulation draws should be the 2nd or 3rd tube drawn
Catheter draws should be avoided or under the advice of the attending physician
All tubes should be inverted at least 4 times to ensure adequate mixing
Suitable needle gauges range from 19 – 22 for coagulation and platelet testing
Cell-free plasma must contain less than 10,000 platelets/µL
Centrifugation should be performed at 1,500 × g for 15 or more minutes
Aliquots are frozen (<= -20ºC) promptly to minimize factor degradation
Specimens are shipped frozen on dry ice (-78.5ºC)
Frozen serum is the specimen of choice for most immunoglobulin detecting assays and many ELISA based tests. Whole blood is drawn into a glass or plastic tube possibly containing an activator. Please follow the tube manufacturer’s guidelines for tube handling and processing.
Please follow the listed suggestions for collection of serum samples.
Plastic tubes containing an activator should be inverted at least 4 times
Glass tubes without activator should be clotted for 2 hours at room temperature
Suitable needle gauges range from 19 – 22 for the serum based tests
Centrifugation should be performed at 1,500 × g for 15 or more minutes
Aliquots are frozen (<= -20ºC) before shipping and shipped on dry ice (-78.5ºC)
EDTA Whole Blood
EDTA anticoagulated whole blood is the specimen of choice for molecular genetic tests.
Please follow the listed suggestions for collection of genetic samples.
Blood should be drawn directly into anticoagulant if possible
Extracted DNA is acceptable if received from CLIA-certified labs
This must be a closed system draw to prevent contamination
All tubes should be inverted at least 4 times to ensure adequate mixing
Suitable needle gauges range from 19 – 22 to prevent cell lysis
A minimum of 2mL of whole blood is needed for genetic assays
No processing is required for this sample type
Ship this type of specimen at room temperature
Submitting multiple aliquots (plasma or serum) for testing is an important aspect of clot, chromogenic and ELISA based tests. Aliquots of 1mL are requested for most of our assays. These should be frozen prior to shipment in a <= -20 C freezer or colder. Tubes should be placed into a rack to ensure the samples are frozen properly in the base of the tube. Freezing should occur within 1 hour of the time of draw. Please refer to the preferred number of aliquots when submitting samples.
Shipment is a crucial aspect of clinical testing. Please follow the below instructions for easy shipments to the lab.
Machaon Diagnostics contracts with Medical Couriers, Inc. (MCI). who service the entire San Francisco Bay Area and surrounding areas. MCI has a fleet of specially trained drivers that will visit your lab, clinic or office during specified times. Couriers carry dry ice, cold packs and room temperature containers for receipt of all specimen types.
Medical Couriers, Inc. can be phoned for individual pickup requests at the below number.
Medical Couriers, Inc. (800)-652-1147
Place prepared samples and order forms in a shipping bag with Machaon and specimen type written in a clear and visible location.
Please collect the following items:
Test Order Form
Packing material or newspaper
Styrofoam container, possibly with outer cardboard box
Airbill for overnight shipments
ORM-A label for dry ice shipments (UN1845)
Dry ice (-78.5ºC) sufficient for transit time (5lb. per day)
Specimens in biohazard specimen transport bag
Place the biohazard bag containing samples and the test order form into a Styrofoam container followed by dry ice. Fill remaining container space with packaging material and seal with packaging tape. Adhere a completed airbill and dry ice labels to the exterior of container in a visible location. Telephone your preferred overnight courier to request a pickup or place container in designated pickup area.
37th Annual Meeting of the Histiocyte Society Meeting
Antiphospholipid Syndrome: criteria, non-criteria and triple positive testing – a video with Dr. Brad Lewis and Dr. Sciascia.
Platelet Functional Defects, from the clinic to genetics (a webinar given by Dr. Brad Lewis, Feb. 24, 2017)
Diagnosing Thrombotic Microangiopathies: TTP and atypical HUS: (A Grand Rounds presentation at Mattel Children’s Hospital, UCLA, to Pediatric Nephrology with Dr. Brad Lewis.)
A guide to the video content:
00:24 – Introduction (Why we should care about diagnosis of aHUS and TTP)
1:00 – What is microangiopathic hemolytic anemia (MAHA)?
1:16 – Blood smear with schistocytes
1:40 – Von Willebrand’s protein synthesis
02:09 – ADAMTS-13 and TTP pathophysiology
02:43 – How to interpret ADAMTS-13 activity testing and advantage of doing ADAMTS-13 activity testing with Machaon Dx
03:48 – Use of ADAMTS-13 testing to diagnose “Occult” TTP
04:40 – Ruling in or out aHUS with ADAMTS-13 activity testing
05:20 – Plasma exchange for aHUS patients
05:57 – The complement cascade and aHUS pathophysiology
08:04 –aHUS patients respond to eculizumab therapy
08:45 – Unlike TTP, aHUS has triggers in 70% of cases
09:26 – aHUS is a multisystem microvascular disease (aHUS-induced organs damage)
10:09 – aHUS presentation
11:41 – Can we differentiate TTP and aHUS clinically?
12:15 – 5 reasons why you should care about aHUS patients genotyping
14:17 – Advantage of doing aHUS genetic testing with Machaon Dx
14:52 – The punchline: aHUS and TTP diagnosis algorithm
Shapiro, AD. et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018;131(12):1301–1310.
Stromsness B. et al. Physician Interpretation of Equivocal Results for aHUS Genetic Testing Varies Greatly and is Frequently at Odds with Laboratory Views. J Clin Apheresis. 2019; (abstract P-82).
Ero, MP, Kain, JS, inventors; Machaon Diagnostics, Inc., assignee. 2018 Dec 18. Method of diagnosis of complement-mediated thrombotic microangiopathies. United States patent US 10,155,983.
Tao J. et al. A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis. BMC Nephrology. 2018;19:355.
Kain J. et al. Additional Genes Associated with Atypical Hemolytic Uremic Syndrome. ASN 2018 Abstract TH-PO713. 2018; (abstract).
Switala L. et al. Complement factor abnormalities detected in patients with suspected Heparin-induced Thrombocytopenia (HIT) but not in Thrombotic Thrombocytopenia Purpura (TTP). ISLH 2017 Abstract Proceedings. 2017; (abstract).
Ipe T. et al. An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome. J Clin Apheresis. 2017;32(6):584-588.
Alge J. et al. Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report. BMC Nephrology. 2017;18(1): 243.
Zhang K. et al. Atypical hemolytic uremic syndrome: a brief review. Hematology Reports. 2017;9(2):7053.
Jensen G. et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: resultd from a randomized double-blind, placebo-controlled, multicenter North American clinical trial. Integrated Blood Pressure Control. 2016;9:95-104.
Stromsness B. et al. Perceived clinical utility of ADAMTS-13 testing decreases quickly when turnaround time extends beyond two days. Int J Lab Hematol. 2015; (abstract).
Ero M. et al. Novel variant detection is essential when attempting to genetically confirm the clinical diagnosis of complement-mediated thrombotic microangiopathies (TMA). J Clin Apheresis. 2015; (abstract O-09).
Harbert J. et al. Inhibitory effects of fish oil on platelet-associated thrombin generation as measured by the calibrated automated thrombogram: an in vitro study. Int Soc Thromb Hemost 2014; (abstract 604).
Ero M. et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2013;38(2):235-240.
Beattie DT. Et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, Velusetrag and TD-8954. J Thromb Thrombolysis. Vascular Pharmacology. 2013;58:150–156.
Ero M. et al. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single oral daily dose. Alternative Therapies. 2013;19(3): 18-21.
Higgins D. et al. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Archives of Pharmacology. 2012;385(1):103-9.
Ng C. et al. Oral bioavailability of nattokinase (NSK-SD). Am J Clin Pathol. 2010;134(suppl):11.
Lakshmi P. et al. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther. 2010;27(7):1-12.
Jeske WP. et al. Isolation and characterization of heparin from tuna skins. Clin Appl Thromb Hemost. 2007 Apr;12(2):137-45.
Fareed D. et al. Nitric oxide levels are upregulated in patients with malignancy-associated hypercoagulable state. Int J Lab Hematol. 2005; (abstract).
Jeske WP. et al. A survey of venous thrombosis models. Methods Mol Med. 2004;93:221-37.
Sahud et al. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002; 116(4):909-911.
Fenton JW. et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry. 2002;67(1):85-91.
Ero M. et al. Comparative effects of a novel sulfated pentamannan oligosaccaride mixture (PI-88), heparin and related agents on the tissue factor-induced platelet activation and aggregation profile in whole blood. Thromb Haemost. 2001; (abstract 6260).
Ero M. et al. An antiplatelet drug, ticlopidine, inhibits heparin-induced thrombocytopenia responses as measured by platelet aggregometry and 14C serotonin release. Thromb Haemostasis. 1997; (abstract).
Clinical Trial Services
Machaon Diagnostics is a clinical reference laboratory, specializing in the diagnosis and monitoring of coagulation, platelet, rare disease and genetics. What makes us unique is our ability to provide high quality custom testing with unmatched speed.
Our Mission is to save more lives with lab tests.
Since 2003, we have grown into a team of clinicians, scientists, consultants and technologists bringing over 400 years of aggregated expertise to the field of laboratory medicine.
Our areas of clinical expertise include: Rare Disease Genetics, Advanced Hemostasis, (Platelets and Coagulation), Complement Disorders, Nephrology, Hematology / Oncology, Ophthalmology, Cardiology, Immunology, and Medical Devices.
Our esoteric and additional routine testing menu applies to a wide variety of disorders and clinical situations and, therefore, draws attention from both a national and an international clientele. Our clients include university medical centers, health system networks, community hospitals, commercial and research laboratories, doctor’s offices, biotechnology firms and pharmaceutical companies of all sizes.
Machaon Diagnostics provides a rapid and complete solution for companies in need of clinical trial services, contract research and independent marketing claim validation. We have been performing studies on pharmaceuticals and medical devices since 2003. Design, subject recruitment, sample collection/storage, testing, statistical analysis, study reporting and manuscript preparation are all included in our comprehensive service. We have an extensive database of well-characterized study volunteers, allowing us to complete some IRB-approved clinical trials in as little as 5 weeks. Our subject database includes normal adult, rare disease, elevated risk of cardiovascular disease, high blood pressure, metabolic syndrome and other populations. We frequently collaborate with our larger CRO partners to aid in global clinical trials.
Research & Development
Machaon Diagnostics is the largest independent specialized coagulation lab in the US. We are a privately-owned company, staffed by MDs, PhDs, licensed clinical laboratory scientists (CLSs) and medical technologists.
As a clinical lab, we provide a unique testing environment for evaluating thrombotic and fibrinolytic potential. Pharmaceutical, device and biotech compounds and materials can be studied within established, validated and controlled clinical assays with verified reference ranges. Our clinical tests are further controlled within our quality assurance and proficiency testing policies and procedures. All tests can be modified or re-designed for best-fit analysis.
The Machaon Diagnostics laboratory facility is located on a medical center campus in Berkeley, California with a second lab site in New Orleans, Louisiana. Our scientists are published in and passionate about the field of laboratory medicine.
Our staff has had extensive experience designing unique testing systems or applying the proper testing system to answer the clinical trial questions quickly and accurately.
Custom-built assays, from ELISAs to NGS, from Sanger to Flow Cytometry, from TEG to Electrophoresis, we build custom assays to complement our pre-existing testing capabilities to fit your testing needs.
Machaon Diagnostics is a multi-state licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.
Machaon (pronounced may-chay-on) is a character from Homer’s Iliad (800 B.C.) and a key figure in the Trojan War. Described as a warrior, surgeon and healer, Machaon was revered for saving the lives of Menelaus, King of Sparta, husband Helen, and that of Philoctetes, the famed Achaean leader. Under the direction of King Agamemnon, Machaon saved these and many other warriors during the fierce Greek and Trojan War.
What you need to know
If you are reading this page, it likely means your doctor has ordered a bleeding or clotting test for you and would like you to get this test run at Machaon Diagnostics. Machaon Diagnostics is a clinical reference lab specializing in bleeding and clotting testing, one of the few independent coagulation labs in the country. We run very specific, unique blood tests which are often critical in helping doctors determine the correct course of treatment.
Machaon Diagnostics provides specialized lab testing to hospitals and doctors all over the country and is recognized for the speed and quality of our testing.
It is important to know that your insurance may or may not cover your testing. We have a long track record of working with patients to ensure they get the testing they need and we will work with you to help find a solution should your insurance not cover the testing we would provide.
If you are coming in to Machaon for a test, here are some things you will need to have with you:
Your doctors lab order
Your insurance information
A list of your current medications
If you are coming in for a Platelet Aggregation, please remember you must fast before this test.
Machaon Diagnostics was founded in 2003 and is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.